Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab

Cited by (1,000)

Items 101–200 of 1,000

1. Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants
   Fanchong Jian, Anna Z. Wec, Leilei Feng, Yuanling Yu, Lei Wang, Peng Wang, Lingling Yu, Jing Wang, Jacob Hou, Daniela Montes Berrueta et al. · 2025 · Nature Microbiology
2. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
   Franck Touret, Cécile Baronti, Boris A. M. Pastorino, Paola Mariela Saba Villarroel, Läétitia Ninove, Antoine Nougaırède, Xavier Nicolas de Lamballerie · 2022 · Scientific Reports
3. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials
   Wei‐Ting Lin, Shun‐Hsing Hung, Chih‐Cheng Lai, Cheng‐Yi Wang, Chao‐Hsien Chen · 2022 · Journal of Medical Virology
4. Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient Patients
   Smaranda Gliga, Nadine Lübke, Alexander Killer, Henning Gruell, Andreas Walker, Alexander Dilthey, Alexander Thielen, Carolin Lohr, Charlotte Flasshove, Sarah Krieg et al. · 2022 · Clinical Infectious Diseases
5. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
   Wenjuan Du, Daniel L. Hurdiss, Dubravka Drabek, Anna Z. Mykytyn, Franziska Karola Kaiser, Mariana González-Hernández, Diego Muñoz‐Santos, Mart Matthias Lamers, Rien van Haperen, Wentao Li et al. · 2022 · Science Immunology
6. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
   Andrew Evans, Cathy Qi, Jubril Omololu Adebayo, Jonathan Underwood, James Coulson, Rowena Bailey, Ronan Anthony Lyons, Adrian Edwards, Alison Cooper, Gareth John et al. · 2023 · Journal of Infection
7. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
   Jessica Hedvat, Nicholas W. Lange, David M. Salerno, Ersilia M. DeFilippis, Danielle Kovac, Heather Corbo, Justin K. Chen, Jason Y. Choe, Jennifer H. Lee, Anastasia Anamisis et al. · 2022 · American Journal of Transplantation
8. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
   Cherrelle Dacon, Linghang Peng, Ting-Hui Lin, Courtney Tucker, Chang-Chun David Lee, Yu Cong, Lingshu Wang, Lauren Purser, Andrew J. R. Cooper, Jazmean K. Williams et al. · 2022 · Cell Host & Microbe
9. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China
   Yang Yang, Liping Guo, Jing Yuan, Zhixiang Xu, Yuchen Gu, Jiaqi Zhang, Yuan Guan, Jinhu Liang, Hongzhou Lu, Yingxia Liu · 2023 · The Lancet Microbe
10. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
    Robert L. Atmar, Natalie Finch · 2022 · Antimicrobial Agents and Chemotherapy
11. Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis
    Mayur Murali, Leher Gumber, Hannah Jethwa, Divolka Ganesh, Jamie Hartmann‐Boyce, Harpreet S. Sood, Francesco Zaccardi, Kamlesh K. Khunti · 2023 · BMC Medicine
12. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2
    Lianghui Zhang, Krishna K. Narayanan, Laura M. Cooper, Kui K. Chan, Savanna S. Skeeters, Christine A. Devlin, Aaron Aguhob, Kristie M. Shirley, Lijun Rong, Jalees Rehman et al. · 2022 · EMBO Molecular Medicine
13. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
    Luca Cegolon, Riccardo Pol, Omar Simonetti, Francesca Larese Filon, Roberto Luzzati · 2023 · Pharmaceuticals
14. Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample
    Lukas Hobohm, Ingo Sagoschen, Stefano Barco, Irene M. Schmidtmann, Christine Espinola–Klein, Stavros Konstantinides, Thomas F. Münzel, Karsten Keller · 2022 · Viruses
15. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
    Robert W. Cross, Zachary A. Bornholdt, Abhishek N. Prasad, Courtney B. Woolsey, Viktoriya Borisevich, Krystle N. Agans, Daniel J. Deer, Dafna M. Abelson, Do H. Kim, William S. Shestowsky et al. · 2022 · JCI Insight
16. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
    Jean W. Liew, Milena A. Gianfrancesco, Carly Harrison, Zara Izadi, Stephanie Rush, Saskia Lawson‐Tovey, Lindsay Jacobsohn, Clairissa Ja, Kimme Leanne Hyrich, Laure Gossec et al. · 2022 · RMD Open
17. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients
    Louise Benning, Christian P. Morath, Marie Bartenschlager, Heeyoung Kim, Marvin Reineke, Jörg Beimler, Mirabel Buylaert, Christian Nußhag, Florian Kälble, Paula Reichel et al. · 2022 · American Journal of Transplantation
18. A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection
    Wanbo Tai, Kai Yang, Yubin Liu, Ruofan Li, Shengyong Feng, Benjie Chai, Xinyu Zhuang, Shaolong Qi, Huicheng Shi, Zhida Liu et al. · 2023 · Nature Communications
19. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
    Paul Bastard, Adrian Gervais, Maki Taniguchi, Liisa Saare, Karita Särekannu, Tom Le Voyer, Quentin Philippot, Jérémie Rosain, Lucy Bizien, Takaki Asano et al. · 2023 · The Journal of Experimental Medicine
20. Development of plant-made monoclonal antibodies against viral infections
    Qiang Chen · 2021 · Current Opinion in Virology
21. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
    Jun Shimizu, Tadahiro Sasaki, Ritsuko Koketsu, Ryo Morita, Yuka Yoshimura, Ami Murakami, Yua Saito, Toshie Kusunoki, Yoshihiro Samune, Emi E. Nakayama et al. · 2022 · Scientific Reports
22. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
    Kuan-Ying Arthur Huang, Xiaorui Chen, Arpita Mohapatra, Hong Thuy Vy Nguyen, Lisa M. Schimanski, Tiong Kit Tan, Pramila Rijal, Susan K. Vester, Rory A. Hills, Mark R. Howarth et al. · 2023 · Nature Communications
23. COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity
    Yandong Shen, Jane A. Freeman, Juliette Holland, Ann Solterbeck, Kartik Naidu, Asha Soosapilla, Paul Downe, Catherine Tang, Ian Kerridge, Lucinda Wallman et al. · 2021 · British Journal of Haematology
24. Comparative evaluation of authorized drugs for treating Covid‐19 patients
    Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam · 2022 · Health Science Reports
25. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review
    Yanis Ramdani, Juliette Lamamy, Hervé Watier, Valérie Gouilleux‐Gruart · 2022 · International Journal of Molecular Sciences
26. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
    Mindy M. Cheng, Carolina M. Reyes, Sacha Satram, Helen J. Birch, Daniel C. Gibbons, Myriam Drysdale, Christopher F. Bell, Anvar Suyundikov, Xiao Xia Ding, M. Cyrus Maher et al. · 2023 · Infectious Diseases and Therapy
27. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study
    Julia Hippisley‐Cox, Kamlesh K. Khunti, Aziz Sheikh, Jonathan S Nguyen-Van-Tam, Carol A. C. Coupland · 2023 · BMJ
28. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
    Sho Iketani, David D. Ho · 2024 · Cell chemical biology
29. COVID-19 therapeutics
    Daniele Focosi, Massimo Franchini, Fabrizio Maggi, Shmuel Shoham · 2024 · Clinical Microbiology Reviews
30. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
    Anselm Jorda, Manuel Kussmann, Nebu Kolenchery, Jolanta Maria Siller-Matula, Markus Alexander Zeitlinger, Bernd Jilma, Georg Gelbenegger · 2022 · Frontiers in Immunology
31. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
    Reem Hoteit, Hadi Mohamad Yassine · 2022 · Vaccines
32. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
    Ana Atti, Ferdinando Insalata, Edward J Carr, Ashley David Otter, Javier Castillo‐Olivares, Mary Wu, Ruth Harvey, Michael T. Howell, Andrew Chan, Jonathan Lyall et al. · 2022 · Journal of Infection
33. COVID-19 Drug Development
    Seungtaek Kim · 2021 · Journal of Microbiology and Biotechnology
34. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
    Maddalena Marconato, Irène A. Abela, Anthony Hauser, Magdalena Schwarzmüller, Rheliana Katzensteiner, Dominique L. Braun, Selina Epp, Annette Audigé, Jacqueline Weber, Peter Rusert et al. · 2022 · Journal of Clinical Investigation
35. Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
    Ahmed Ali Al-Karmalawy, Raya Soltane, Ayman Abo Elmaaty, Mohamed A. Tantawy, Samar A. Antar, Galal Yahya, Amani Chrouda, Rami Adel Pashameah, Muhamad Mustafa, Mobarak Abu Mraheil et al. · 2021 · Vaccines
36. Immunocompromised patients have been neglected in COVID-19 trials: a call for action
    Marius Trøseid, Maxime Hentzien, Florence Ader, Sandra Wagner Cardoso, José Ramón Arribas, Jean‐Michel Molina, Nicolas Johannes Mueller, Maya Hites, Fabrice Bonnet, Oriol Manuel et al. · 2022 · Clinical Microbiology and Infection
37. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
    Kara W Chew, Carlee Moser, Eric S. Daar, David Alain Wohl, Jonathan Z. Li, Robert W. Coombs, Justin Ritz, Mark J Giganti, Arzhang Cyrus Javan, Yijia Li et al. · 2022 · Nature Communications
38. Monoclonal antibody therapies in the management of SARS-CoV-2 infection
    Enrique Míguez Rey, Dasom Choi, Seungmin Kim, Sangwook Yoon, Oana Săndulescu · 2022 · Expert Opinion on Investigational Drugs
39. Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
    Akshita Gupta, Angelina Konnova, Mathias Smet, Matilda Berkell, Alessia Savoldi, Matteo Morra, Vincent Van averbeke, Fien De Winter, Denise Peserico, Elisa Danese et al. · 2023 · Journal of Clinical Investigation
40. Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry
    Julius J. Schmidt, Dan Nicolae Borchina, Mariet van ́t Klooster, Khalida Soki, Reuben Okioma, Larissa Herbst, Diego Rodríguez, Vedran Premužić, Stefan Büttner, Birgit D. Bader et al. · 2021 · Nephrology Dialysis Transplantation
41. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States
    Manuela Di Fusco, Kinga Marczell, Kristen A. Deger, Mary M. Moran, Timothy Lee Wiemken, Alejandro D. Cane, Solène de Boisvilliers, Jingyan Yang, Shailja Vaghela, Julie Roïz · 2022 · Journal of Medical Economics
42. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
    Dean A. Follmann, Meagan P. O’Brien, Jonathan Fintzi, Michael P. Fay, David C. Montefiori, Allyson Mateja, Gary A. Herman, Andrea T. Hooper, Kenneth C. Turner, K.-C. Chan et al. · 2023 · Nature Communications
43. A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro
    Jing Sun, Deheng Sun, Qi Yang, Dong Wang, Jingjing Peng, Hu Guo, Xiaoyu Ding, Chen Zhao, Bin Yuan, Yan A. Ivanenkov et al. · 2025 · Nature Communications
44. Guideline for the treatment of chronic lymphocytic leukaemia
    Renata J. Walewska, Nilima Parry‐Jones, Toby Andrew Eyre, George Follows, Nicolás Martínez‐Calle, Helen O. McCarthy, Helen Parry, Piers Patten, John Charles Riches, Peter Hillmen et al. · 2022 · British Journal of Haematology
45. Omicron – The new SARS‐CoV‐2 challenge?
    Alexandra Lino, Marita A. Cardoso, Paula Martins‐Lopes, Helena M. R. Gonçalves · 2022 · Reviews in Medical Virology
46. In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein
    Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, Suprabhat Mukherjee · 2022 · Frontiers in Immunology
47. Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
    K. Gary Barnette, Michael S. Gordon, Domingo Rodriguez, T. Gary Bird, Alan Skolnick, Michael J. Schnaus, Paula K. Skarda, Suzana M. Lobo, Eduardo Sprinz, Georgi Arabadzhiev et al. · 2022 · NEJM Evidence
48. Molecular Mechanisms Related to Responses to Oxidative Stress and Antioxidative Therapies in COVID-19: A Systematic Review
    Evangelia Eirini Tsermpini, U. Glamočlija, Fulden Ulucan‐Karnak, Sara Redenšek Trampuž, V. Dolžan · 2022 · Antioxidants
49. A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort
    Pablo Barreiro, Juan Carlos Sanz, Jesús San Román, Marta Pérez-Abeledo, Mar Carretero, Gregoria Megías, José Manuel Viñuela-Prieto, Belén Ramos, Jesús Canora, Francisco Javier Martínez-Peromingo et al. · 2022 · Journal of Clinical Microbiology
50. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
    Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, Khai Li Chai, Lise J Estcourt, Ina Monsef, Susanne Salomon, Erica M. Wood, Cynthia So‐Osman, Zoe McQuilten et al. · 2022 · Cochrane Database of Systematic Reviews
51. Outcome of early treatment of SARS‐CoV ‐2 infection in patients with haematological disorders
    Małgorzata Mikulska, Diletta Testi, Chiara Russo, Elisa Balletto, Chiara Sepulcri, Linda Bussini, Chiara Dentone, Federica Magnè, S. Negre Policarpo, Caterina Campoli et al. · 2023 · British Journal of Haematology
52. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch
    Zachary A. Yetmar, Elena N. Beam, John Charles O’Horo, Maria Teresa Seville, Lisa M. Brumble, Ravindra Ganesh, Raymund Rabe Razonable · 2022 · Transplant Infectious Disease
53. Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
    2022
54. Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark
    Sebastian Rask Hamm, Omid Rezahosseini, Dina Leth Møller, Josefine Amalie Loft, Johan Runge Poulsen, Jenny Dahl Knudsen, Martin Schou Pedersen, Kristian Schønning, Zitta Barrella Harboe, Allan Rasmussen et al. · 2022 · American Journal of Transplantation
55. Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
    Daniele Focosi, Arturo Casadevall, Massimo Franchini, Fabrizio Maggi · 2024 · Viruses
56. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
    Kamyab Javanmardi, Thomas H. Segall-Shapiro, Chia‐Wei Chou, Daniel R. Boutz, Randall J. Olsen, Xuping Xie, Hongjie Xia, Pei‐Yong Shi, Charlie D. Johnson, Ankur Annapareddy et al. · 2022 · Cell Host & Microbe
57. Comorbidities Associated with Hospitalization and Progression Among Adolescents with Symptomatic Coronavirus Disease 2019
    Jeffrey I. Campbell, Melanie M. Dubois, Timothy J. Savage, M. Indriati Hood-Pishchany, Tanvi S. Sharma, Carter R. Petty, Gabriella S Lamb, Mari Nakamura · 2022 · The Journal of Pediatrics
58. Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
    Juthaporn Cowan, Ashley Amson, Anna Christofides, Zain Chagla · 2023 · International Journal of Infectious Diseases
59. Treatments for COVID-19: Lessons from 2020 and new therapeutic options
    Fanny Salasc, Thomas Lahlali, Emilie Laurent, Manuel Rosa‐Calatrava, Andrés Pizzorno · 2021 · Current Opinion in Pharmacology
60. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
    Irina A. Favorskaya, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Inna V. Dolzhikova, Irina A. Alekseeva, Anastasia I. Korobkova, Daria V. Voronina, Ekaterina I. Ryabova, Artem A. Derkaev, Ковыршина Анна Витальевна et al. · 2022 · Frontiers in Immunology
61. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
    David M. Lowe, Li‐An K. Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai et al. · 2022 · PLoS Medicine
62. Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
    M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, Alpana Waghmare, Maheen Z. Abidi, Steven A. Pergam, Michael Boeckh, Sanjeet Dadwal, Mini Kamboj, Susan K. Seo et al. · 2022 · Transplantation and Cellular Therapy
63. Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch
    Raymund Rabe Razonable, John Charles O’Horo, Sara N. Hanson, Richard F. Arndt, Leigh Lewis Speicher, Teresa A Seville, Scott T. Hall, Marsha L. Pike, Alexander Heyliger, Jennifer J. Larsen et al. · 2022 · The Journal of Infectious Diseases
64. Anti-glycan monoclonal antibodies: Basic research and clinical applications
    Kara M. Gillmann, J. Sebastian Temme, Samantha Marglous, Claire E. Brown, Jeffrey C. Gildersleeve · 2023 · Current Opinion in Chemical Biology
65. Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
    Eugenia Quirós-Roldán, Silvia Amadasi, Isabella Zanella, Melania Degli Antoni, Samuele Storti, Giorgio Tiecco, Francesco Castelli · 2021 · Pharmaceuticals
66. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
    Laura Matrajt, Elizabeth R. Brown, Myron S. Cohen, Dobromir Dimitrov, Holly Janes · 2022 · BMC Infectious Diseases
67. Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
    Federico Baldi, Chiara Dentone, Małgorzata Mikulska, Daniela Fenoglio, Michele Mirabella, Federica Magnè, Federica Portunato, Tiziana Altosole, Chiara Sepulcri, Daniele Roberto Giacobbe et al. · 2023 · Frontiers in Medicine
68. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial
    Fuxiang Wang, Wen Xiao, Yimin Tang, Mengli Cao, Dan Shu, Tetsuya Asakawa, Yechun Xu, Xiangrui Jiang, Leike Zhang, Wei Wang et al. · 2023 · The Lancet Regional Health - Western Pacific
69. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants
    Michael Korenkov, Matthias Zehner, Hadas Cohen‐Dvashi, Aliza Borenstein-Katz, Lisa Kottege, Hanna Janicki, Kanika Vanshylla, Timm Weber, Henning Gruell, Manuel Koch et al. · 2023 · Immunity
70. Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis
    David J. Sullivan, Daniele Focosi, Daniel F. Hanley, Mario Cruciani, Massimo Franchini, Jiangda Ou, Arturo Casadevall, Nigel Paneth · 2023 · Journal of Medical Virology
71. Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: a systematic review and meta-analysis
    Karen M Elias, Shanchita Rahnuma Khan, Eva Stadler, Timothy E. Schlub, Deborah Cromer, Mark Niccolo Polizzotto, Stephen John Kent, Tari Turner, Miles P. Davenport, David S. Khoury · 2024 · The Lancet Microbe
72. The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
    Yao Jiang, Qian Yun Wu, Peipei Song, Chongge You · 2022 · Frontiers in Medicine
73. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
74. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
    Justin C. Laracy, Mini Kamboj, Santosha Adipudi Vardhana · 2022 · Current Opinion in Infectious Diseases
75. Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients
    Matthew K. Wynia, Laurel E. Beaty, Tellen D. Bennett, Nichole E. Carlson, Christopher B. Davis, Bethany M. Kwan, David A. Mayer, Toan C. Ong, Seth Russell, Jeffrey Steele et al. · 2022 · CHEST Journal
76. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
    Anna-Lena Mader, Leonid Tydykov, Vivian Glück, Manuela Bertok, Tanja Weidlich, Christine Gottwald, Alexa Stefl, Matthias Vogel, Annelie Plentz, Josef Köstler et al. · 2022 · iScience
77. Upstream cell culture process characterization and in-process control strategy development at pandemic speed
    Jianlin Xu, Jianfa Ou, Kyle P. McHugh, Michael Borys, Anurag Khetan · 2022 · mAbs
78. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
    Amelia C. A. Green, Helen J Curtis, Rose Higgins, Linda Nab, Viyaasan Mahalingasivam, Rebecca M. Smith, Amir Mehrkar, Peter Inglesby, Henry Drysdale, Nicholas DeVito et al. · 2023 · BMJ Medicine
79. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
    Teresa H. Evering, Kara W Chew, Mark J Giganti, Carlee Moser, Mauricio Pinilla, David Alain Wohl, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Rachel Bender Ignacio et al. · 2023 · Annals of Internal Medicine
80. Non-coding RNAs expression in SARS-CoV-2 infection: Pathogenesis, clinical significance and therapeutic targets
    Xiao-Xing Liu, Wandi Xiong, Maosen Ye, Tang-Sheng Lu, K. Yuan, Suhua Chang, Ying Han, Yong-Xiang Wang, Lin Lu, Yan-Ping Bao · 2023 · Signal Transduction and Targeted Therapy
81. Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products
    Brian D. Kelley, Pam De Moor, Kristen Douglas, Todd Renshaw, Stacey L. Traviglia · 2022 · Current Opinion in Biotechnology
82. Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis
    Bahman Amani, Behnam Amani · 2022 · Reviews in Medical Virology
83. SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo
    Emi E. Nakayama, Tatsuo Shioda · 2023 · Microorganisms
84. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
    Nathalie Chavarot, Cléa Melenotte, Lucile Amrouche, Claire Rouzaud, Rébecca Sberro‐Soussan, Juliette Pavie, Frank Martinez, Anne Pouvaret, Marianne Leruez‐Ville, Delphine Cantin et al. · 2022 · Kidney International
85. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity
    Minghui Yang, Chunhui Li, Guoguo Ye, Chenguang Shen, Huiping Shi, Liping Zhong, Yuxin Tian, Mengyuan Zhao, Pengfei Wu, Abid Hussain et al. · 2024 · Signal Transduction and Targeted Therapy
86. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
    ACTIV-3/TICO Study Group*, Christina Barkauskas, Eleftherios E Mylonakis, Garyfallia Poulakou, Barnaby Edward Young, David M. Vock, Lianne K. Siegel, Nicole Wyman Engen, Greg Grandits, Nilima R. Mosaly et al. · 2022 · Annals of Internal Medicine
87. Viral load decrease in SARS‐CoV‐2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents
    Valentina Mazzotta, Alessandro Cozzi‐Lepri, Francesca Colavita, Silvia Rosati, Eleonora Lalle, Claudia Cimaglia, Jessica Paulicelli, Ilaria Mastrorosa, Serena Vita, Lavinia Fabeni et al. · 2022 · Journal of Medical Virology
88. Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
    Nalini Ambrose, Alpesh Amin, Brian Anderson, Julio G. Barrera-Oro, Monica M. Bertagnolli, Francis X. Campion, Daniel S. Chow, Risa Danan, Lauren D’Arinzo, Ashley L. Drews et al. · 2023 · JAMA Network Open
89. A database of anti-coronavirus peptides
    Qianyue Zhang, Xue Chen, Bowen Li, Chunying Lu, Shanshan Yang, Jinjin Long, Heng Chen, Jian Hua Huang, Bifang He · 2022 · Scientific Data
90. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
    Joshua Wolf, Mark J. Abzug, Brenda I. Anosike, Surabhi B Vora, Alpana Waghmare, Paul K. Sue, Rosemary M. Olivero, Carlos R. Oliveira, Scott H. James, Ted Morton et al. · 2021 · Journal of the Pediatric Infectious Diseases Society
91. Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics
    Emanuel Wyler, Julia Maria Adler, Kathrin Eschke, Gustavo Teixeira Alves, Stefan Peidli, Fabian Pott, Julia Kazmierski, Laura Michalick, Olivia Kershaw, Judith Bushe et al. · 2022 · Molecular Therapy
92. A guide to COVID ‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV ‐2 infection
    Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, Ali A. Hussain, Audrey L Lingan, Olivia G. Pembridge, Brina A. Ratangee, Tristan T. Sealy, Kyle T Vallone, Thomas P. Clements · 2022 · FEBS Journal
93. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
    Qiugang Zhu, Yan Xu, Ting Wang, Feiting Xie · 2022 · Frontiers in Immunology
94. Navigating the Post-COVID-19 Immunological Era: Understanding Long COVID-19 and Immune Response
    Aditi Mohan, Venkatesh Anand Iyer, Dharmender Kumar, Lalit Batra, Praveen Dahiya · 2023 · Life
95. Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
    Bright Thilagar, Aditya Kumar Ghosh, Jerome Nguyen, Regan N. Theiler, Myra J. Wick, Ryan T. Hurt, Raymund Rabe Razonable, Ravindra Ganesh · 2022 · Obstetrics and Gynecology
96. Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients
    Juliette Gueguen, Charlotte Colosio, Arnaud Del Bello, Anne Scemla, Yohan N’Guyen, Claire Rouzaud, Claudia Carvalho-Schneider, Gabriela Gautier-Vargas, Pierre Tremolières, Arwa Jalal Eddine et al. · 2022 · Kidney International Reports
97. Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
    Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, Fangwen Zhou, Daniel G. Rayner, Shayan Heybati · 2022 · Infection
98. HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment
    Dimitris Basoulis, Elpida Mastrogianni, Pantazis-Michail Voutsinas, Mina Psichοgiou · 2023 · Viruses
99. Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework
    Laure‐Alix Clerbaux, Maria Cristina Albertini, Núria Amigó, Anna Beronius, Gillina F. G. Bezemer, Sandra Coecke, Evangelos P. Daskalopoulos, Giusy del Giudice, Dario Greco, Lucia Grenga et al. · 2022 · Journal of Clinical Medicine
100. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19: a randomized placebo-controlled trial
     Arvind Gharbharan, Carlijn C. E. Jordans, Lisa Zwaginga, Grigorios Papageorgiou, Nan van Geloven, Peter van Wijngaarden, Jan den Hollander, Faiz Karim, Elena van Leeuwen-Segarceanu, Robert Soetekouw et al. · 2022 · Clinical Microbiology and Infection